Remogliflozin etabonate
| CAS No. | 442201-24-3 | Cat. No. | BCP16294 |
| Name | Remogliflozin etabonate | ||
| Synonyms | GSK189075A; GSK-189075A; GSK 189075A; GSK189075;GSK-189075;GSK 189075;KGT-1681;KGT 1681;KGT1681; | ||
| Formula | C26H38N2O9 | M. Wt | 522.59 |
| Description | Remogliflozin etabonate is a SGLT2 inhibitor under development for the treatment of type 2 diabetes. Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Remogliflozin is selective for SGLT2. | ||
| Pathways | Ion Channel/Membrane Transporter GPCR/G Protein | ||
| Targets | SGLT | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.